Skip to main content
Log in

Inhaled glucocorticoids are associated with vertebral fractures in COPD patients

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Chronic obstructive pulmonary disease (COPD) is an independent risk factor for osteoporosis. Oral glucocorticoids are deleterious to bone; however, the impact of inhaled glucocorticoids (ICS) remains unclear. Our objective was to determine whether ICS contribute to osteoporosis and fragility fractures. Sixty-one COPD patients, 35 current users of ICS and 26 who had never received glucocorticoids, were evaluated for bone mineral density (BMD) and body composition and underwent vertebral fracture assessment (VFA). The risk factors for bone disease considered for analysis were age, gender, ICS use, body mass index (BMI), muscle mass index (MMI), and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) category. The Fracture Risk Assessment Tool (FRAX) calculation tool for the Brazilian population was also employed. The groups did not differ regarding gender, BMI, MMI, GOLD class, lowest values of the BMD T-score and Z-score, prevalence of osteoporosis, or low BMD for age. Vertebral fractures were identified via VFA in seven patients using ICS and in none of those not receiving glucocorticoids (p = 0.02). There was a trend for an association between MMI and osteoporosis (p = 0.05) and for a progressive decrease in the BMD Z-score according to the COPD severity assessed via the GOLD score (p = 0.08). Vertebral fractures were not associated with osteoporosis (p = 0.69) or low MMI (p = 0.12). The fracture risk was not estimated by FRAX. ICS may lead to bone fragility before a significant decrease in BMD. Low muscle mass and COPD severity may contribute to bone disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C et al (2013) Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187:347–365

    Article  PubMed  CAS  Google Scholar 

  2. Law MR, Hackshaw AK (1997) A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of major effect. BMJ 315:841–846

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Gan WQ, Man SF, Senthilselvan A, Sin DD (2004) Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59:574–580

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Bolton CE, Ionescu AA, Shields KM, Pettit RJ, Edwards PH (2004) Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170:1286–1293

    Article  PubMed  Google Scholar 

  5. Jorgensen NR, Schwarz P, Holme L, Henriksen BM, Petersen LJ, Backer V (2007) The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross-sectional study. Respir Med 101:177–185

    Article  PubMed  CAS  Google Scholar 

  6. Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA (2009) Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 34:209–218

    Article  PubMed  CAS  Google Scholar 

  7. Maggi S, Siviero P, Gonnelli S, Schiraldi C, Malavolta N et al (2009) Osteoporosis risk in patients with chronic obstructive pulmonary disease: the EOLO Study. J Clin Densitom 12:345–352

    Article  PubMed  CAS  Google Scholar 

  8. Majumdar SR, Villa Roel C, Lyons KJ, Rowe BH (2010) Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. Respir Med 104:260–266

    Article  PubMed  Google Scholar 

  9. Gonnelli S, Caffarelli C, Maggi S, Guglielmi G, Siviero P et al (2010) Effect of inhaled glucocorticoids and beta2 agonists on vertebral fracture risk in COPD patients: the EOLO study. Calcif Tissue Int 87:137–143

    Article  PubMed  CAS  Google Scholar 

  10. Watanabe R, Tanaka T, Aita K, Hagiya M, Homma T (2015) Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J Bone Miner Metab 33:392–400

    Article  PubMed  Google Scholar 

  11. Dubois EF, Roder E, Dekhuijzen R, Zwinderman AE, Schweitzer DH (2002) Dual X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. Chest 121:1456–1463

    Article  PubMed  CAS  Google Scholar 

  12. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B et al (2014) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation. Osteoporos Int 25:2359–2381

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Johnell O, Pauwels R, Löfdahl CG, Laitinen LA, Postma DS et al (2002) Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 19:1058–1063

    Article  PubMed  CAS  Google Scholar 

  14. Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E et al (2003) Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 14:179–190

    Article  PubMed  CAS  Google Scholar 

  15. Wilkie M, Finch S, Schembri S (2015) Inhaled corticosteroids for chronic obstructive pulmonary disease: the shifting treatment paradigm. COPD 12:582–590

    Article  PubMed  PubMed Central  Google Scholar 

  16. Papaioannou A, Parkinson W, Ferko N, Probyn L, Ioannidis G et al (2003) Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int 14:913–917

    Article  PubMed  CAS  Google Scholar 

  17. Schlaich C, Minne HW, Bruckner T, Wagner G, Gebest HJ et al (1998) Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 8:261–267

    Article  PubMed  CAS  Google Scholar 

  18. Carter JD, Patel S, Sultan FL, Thompson ZJ, Margaux H et al (2008) The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med 102:1165–1172

    Article  PubMed  Google Scholar 

  19. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE et al (2001) Identification and fracture outcomes of undiagnosed low mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822

    Article  PubMed  CAS  Google Scholar 

  20. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone (NY) 34:195–202

    Article  CAS  Google Scholar 

  21. Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328

    Article  PubMed  CAS  Google Scholar 

  22. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten-year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995

    Article  PubMed  CAS  Google Scholar 

  23. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML et al (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395

    Article  PubMed  Google Scholar 

  24. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK et al (2004) Official positions of the International Society for clinical densitometry. J Clin Endocrinol Metab 89:3651–3655

    Article  PubMed  CAS  Google Scholar 

  25. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T et al (2010) Sarcopenia: European consensus on definition and diagnosis. Age Ageing 39:412–423

    Article  PubMed  PubMed Central  Google Scholar 

  26. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fracture in osteoporosis. J Bone Miner Res 11:984–996

    Article  PubMed  CAS  Google Scholar 

  27. Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS (1999) Declining bone mass in men with chronic obstructive pulmonary disease: contribution of glucocorticoids treatment, body mass index, and gonadal function. Chest 116:1616–1624

    Article  PubMed  CAS  Google Scholar 

  28. McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W et al (1998) Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:704–709

    Article  PubMed  CAS  Google Scholar 

  29. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G (2002) Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003537

  30. Graat-Verboom L, Smeenk FW, van den Borne BE, Spruit MA, Jansen FH et al (2012) Progression of osteoporosis in patients with COPD: a 3-year follow-up study. Respir Med 106:861–870

    Article  PubMed  Google Scholar 

  31. Fergusson GT, Calverley MA, Anderson JA, Jenkins CR, Jones PW et al (2009) Prevalence and progression of osteoporosis in patients with COPD: results from the Towards a Revolution in COPD Health Study. Chest 136:1457–1465

    Article  Google Scholar 

  32. Pauwels RA, Lofdahl GC, Laitinen LA, Schouten JP, Postma DS et al (1999) Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340:1948–1953

    Article  PubMed  CAS  Google Scholar 

  33. De Vries F, van Staa TP, Bracke MS, Cooper C, Leufkens HG, Lammers JW (2005) Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 25:879–884

    Article  PubMed  Google Scholar 

  34. Mathioudakis AG, Amanetopoulou SG, Gialmanidis IP, Chatzimavridou-Grigoriadou V, Siasos G et al (2013) Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial? Respirology 18:147–153

    Article  PubMed  Google Scholar 

  35. Elmståhl S, Ekström H, Johnell O, Gerhardsson de Verdier M, Norjavaara E (2006) No association between inhaled corticosteroids and whole body DXA in postmenopausal women. Pharmacoepidemiol Drug Saf 15:527–535

    Article  PubMed  Google Scholar 

  36. Loke YK, Cavallazzi R, Singh S (2011) Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66:699–708

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the Division of Pneumology at the Hospital Universitario Clementino Fraga Filho HUCFF-UFRJ for the collaboration.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pedro Assed Gonçalves.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Appendix

Appendix

See Table 5.

Table 5 Means and standard deviations of all data obtained from bone densitometry in all subgroups studied

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gonçalves, P.A., dos Santos Neves, R., Neto, L.V. et al. Inhaled glucocorticoids are associated with vertebral fractures in COPD patients. J Bone Miner Metab 36, 454–461 (2018). https://doi.org/10.1007/s00774-017-0854-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-017-0854-3

Keywords

Navigation